Oscar Health, Inc.

Oscar Health, Inc. (NYSE: OSCR) is a healthcare technology company built around a fully integrated, end-to-end platform. It generates value through its insurance business and the +Oscar technology platform, with a core focus on the individual health insurance market. The Company primarily serves individuals and families purchasing coverage via Affordable Care Act–established exchanges, including both federally administered and select state-based marketplaces.

As per US Dailies Report published on ‘OSCR’ on Feb 10, 2026, Kalkine provided an ‘Buy’ stance on the stock at USD 12.66 based on fundamental analysis and the stock price has now moved up by ~ 14.14% since then.

Noted below are the details of support and resistance levels provided in our previous report:

Rationale:

Despite strong revenue growth and expanding membership, Oscar Health’s elevated medical costs, rising loss ratios, and reversal to operating and net losses in 2025 highlight persistent margin pressures and execution challenges. Uncertainty around risk adjustment outcomes, regulatory exposure, and the need to effectively translate scale and technology investments into sustainable profitability suggest that near-term financial performance may remain constrained, warranting a more cautious stance on the company’s outlook.

Share Price Chart  

Conclusion

Elevated medical costs and a deteriorating loss ratio, despite strong revenue growth, suggesting a, a "Sell" is recommendation on Oscar Health, Inc. (NYSE: OSCR) has been given at the closing market price of USD 14.45 as on 10 April 2026.

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is 10 April 2026. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level which the stock is expected to reach as per the relative valuation method and/or technical analysis taking into consideration both short-term and long-term scenario.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the London Stock Exchange (LSE) and or REFINITIV. Typically, both sources (LSE and or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.’

Note 6: Dividend Yield may vary as per the stock price movement.